Chikungunya virus outbreak kills six on France's Réunion Island
Six people have died from chikungunya on the French overseas department of Réunion Island since the start of the year, health officials confirmed on Wednesday. The mosquito-borne virus has infected more than 33,000 people on the island so far.
The deaths, between 10 and 30 March, were of people aged over 70 with underlying health conditions, the latest bulletin from France's public health agency, Santé Publique France said.
The agency also said that several other deaths were being investigated to determine whether the virus was a factor.
An epidemic was declared on Réunion Island on 13 January, following a surge in cases that began in August 2024.
Health officials linked the outbreak to rising mosquito numbers during the summer and low immunity levels in the island's population of around 900,000.
Health officials say the situation remains serious, despite some early signs of improvement.
Reunion Island launches emergency health plan amid chikungunya epidemic
Chikungunya is spread by Aedes mosquitoes and causes fever, a rash and joint pain. It can be particularly dangerous for older people, pregnant women, babies and those with chronic illnesses.
In the week from 31 March to 6 April, a total of 4,913 new cases were confirmed, down from nearly 6,300 the week before.
Read more on RFI EnglishRead also:Cyclone death toll rises to four on ravaged French islandTwo die from chikungunya as virus spreads on France's Reunion IslandRéunion Island company revives ancient fermentation technique to boost health
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Sanofi to acquire Blueprint for up to $9.5B
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Looking to further amp up its immunology business, Sanofi has agreed to acquire Blueprint Medicines in a deal that could be worth as much as $9.5 billion. Blueprint's research revolves around an enzyme made by a gene called KIT. This 'tyrosine kinase' enzyme helps control cell development, division and survival, so if it mutates, it can spur the type of uncontrolled cell growth seen in cancer and some rare diseases. Blueprint already has one medicine approved by the Food and Drug Administration, Ayvakit, and is working on a handful of others, two of which are in human testing. The FDA first approved Ayvakit in early 2020 for a rare kind of hard-to-treat gastrointestinal tumor, and specifically for the small subset of adults who have these tumors and certain mutations. Since then, the agency cleared the medicine as a treatment for both the less and more aggressive forms of 'systemic mastocytosis,' an uncommon disorder where a kind of white blood cell known as a mast cell builds up in the bone marrow, digestive tract, skin and other organs. The accumulation can lead to severe inflammation and organ damage. Last year, Blueprint posted $479 million in net product revenue from Ayvakit. The company used to have another marketed cancer drug, Gavreto, which it was co-developing and commercializing with Roche. But Roche ultimately backed away from that alliance, leading Blueprint to sell away rights to Rigel Pharmaceuticals in early 2024. In a statement announcing the deal, Sanofi highlighted the recent trajectory in Ayvakit sales. They were up more than 60%, for example, between the first quarter of 2024 and the same three-month period this year. Blueprint recorded a $67 million net loss in 2024, compared to a more than half-a-billion-dollar net loss in each of the previous two years. The proposed acquisition 'represents a strategic step forward in our rare and immunology portfolios,' Sanofi CEO Paul Hudson said in the Monday statement. 'It enhances our pipeline and accelerates our transformation into the world's leading immunology company.' Hudson added that his company maintains a 'sizeable capacity for further acquisitions.' After being an active dealmaker over the past few years, the French pharmaceutical giant still had close to 8 billion euros in cash and cash equivalents at the end of March. Sanofi bought the diabetes drug developer Provention Bio for almost $3 billion in 2023 and the rare disease-focused Inhibrix for $2.2 billion in 2024. And just last month, it agreed to spend $470 million on Vigil Neuroscience, a Massachusetts-based biotechnology company touting an Alzheimer's disease drug that just finished an early-stage human study. Similar to its Vigil proposal, Sanofi is offering Blueprint investors a so-called contingent value right that could be worth up to $6 per Blueprint share, provided one of the biotech's experimental drugs, 'BLU-808,' hits certain development and regulatory goals. BLU-808 is in mid-stage testing as a possible treatment for chronic hives and an allergy-related condition that causes runny eyes and a congested nose. Blueprint also believes the drug could be useful in treating allergic asthma and 'mast cell activation syndrome.' Another Blueprint drug, elenestinib, is further along, having advanced to a late-stage study for the slower-moving form of systemic mastocytosis. Sanofi's upfront payment of $9.1 billion values Blueprint shares at $129 apiece, reflecting a premium of about 27% from the biotech's closing stock price on Friday. The transaction is expected to close sometime between July and the end of September, according to Sanofi. Andrew Berens, an analyst at the investment firm Leerink Partners, wrote in a note to clients how his team expected Blueprint to land on the 'strategic radar of large pharma' given Ayvakit is on the path to $1 billion or more in annual sales and the company recently raised its financial guidance for this year. However, the deal came sooner than anticipated, ahead of a key data readout for a rival drug from Cogent Biosciences. Cogent's bezuclastinib is also being evaluated as a treatment for systemic mastocytosis, with results set to arrive in the next couple months. Regardless of how strong or weak those results will be, Berens believes they'd serve as a tailwind for Blueprint 'by removing a key overhang and allowing a strategic acquirer to structure a deal based on assumptions about ... market dynamics.' As such, Cogent's data could have propped up Blueprint's share price, 'which may have been an impetus for Sanofi to do the deal now,' Berens posited. Even so, the analyst still sees Sanofi's bid as a positive for Blueprint and this field of research. Cogent shares were down by about 2% late Monday morning. Recommended Reading Blueprint wins key FDA approval for rare disease drug Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Porn sites block access in protest against new French restrictions
From Wednesday, people in France will no longer be able to access pornography on several major sites - at least temporarily. Aylo, the company behind Pornhub, Redtube and Youporn, plans to block content from the afternoon onwards in protest at new French age verification regulations, local media reports said on Tuesday. Instead of porn, the company will only display a statement on the new regulations in the country. Figures from the French digital regulatory authority Arcom from 2023 suggest 2.3 million minors visited porn sites every month, accounting for 12% of the total number of users in the country. To better protect minors, the platforms are to create stricter control mechanisms. Simply clicking that you are over 18 will no longer be enough. To maintain anonymity, external sites will verify the age of users. The porn sites will then only receive confirmation that the person is of legal age and will not know their identity. The external service provider will know the identity of the user but not the reason for the age check. Aylo is in favour of age verification, but says it should be done on the devices used, not on the websites visited. "Lying and taking hostages when you don't want to comply with the law is unacceptable," France's Deputy Minister for Digital Affairs, Clara Chappaz, commented on X in response to the company's announcement. She said the regulation was about protecting children, and other websites were already complying with the new regulation. "If Aylo would rather leave France than apply our law, they are free to do so."
New York Post
3 hours ago
- New York Post
A 200-year-old condom decorated with erotic art goes on display in famous Dutch museum
The Netherlands' national museum has a new object on display that merges art with Amsterdam's infamous Red Light District: a nearly 200-year-old condom, emblazoned with erotic art. The Rijksmuseum said in a statement that the playful prophylactic, believed to be made around 1830 from a sheep's appendix, 'depicts both the playful and the serious side of sexual health.' 3 The condom is believed to be made around 1830 from a sheep's appendix. AP It is part of an exhibition called 'Safe Sex?' about 19th century sex work that opened on Tuesday. The condom, possibly a souvenir from a brothel, is decorated with an erotic image of a nun and three clergymen. 3 The condom, possibly a souvenir from a brothel, is decorated with an erotic image of a nun and three clergymen. Rijksmuseum/AFP via Getty Images 3 The Rijksmuseum said in a statement that the playful prophylactic 'depicts both the playful and the serious side of sexual health.' SakhanPhotography – The phrase 'This is my choice' is written along the sheath in French. According to the museum, this is a reference to the Pierre-Auguste Renoir painting 'The Judgment of Paris,' which depicts the Trojan prince Paris judging a beauty contest between three goddesses. The condom is on display until the end of November.
